Multi-use torasemide composition
A kind of technology of torasemide and composition, applied in the field of water-containing composition
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0062] Example 1: Preparation of a composition according to the invention
[0063] Preparation of mixture 1:
[0064] Water and tromethamine (buffer) were introduced at room temperature (18-25° C.) with stirring by a deflocculation turbine (speed: 200-600 RPM, duration: about 15 minutes).
[0065] Preparation of mixture 2:
[0066] Torsemide was added to Mixture 1 with stirring by a deflocculation turbine (speed: 200-600 RPM, duration: about 15 minutes).
[0067] Preparation of mixture 3:
[0068] Polymer was gradually added to Mixture 2 with agitation by deflocculation turbine and mechanical agitation (speed: 200-600 RPM, duration: about 15 minutes).
[0069] Preparation of mixture 4:
[0070] The remaining excipients (except the organic solvent) were added to mixture 3 and kept stirring until a clear solution was obtained.
[0071] Preparation of mixture 5:
[0072] Then, an organic solvent (propylene glycol) was added to the mixture 4 and kept stirring until...
Embodiment 2
[0080] Example 2: Optimized Stability of Compositions According to the Invention
[0081] Compositions 1 and 2 were evaluated for stability under accelerated harsh storage conditions: at a temperature of 40°C, at a relative humidity of 75% and for a period of T = 2 months.
[0082] For each composition tested, the level of impurities is measured by the method corresponding to the active ingredient, described in the European or US Pharmacopoeia monographs.
[0083] The results are listed in Table 2 below:
[0084]
[0085] Table 2: Stability tests of compositions 1 and 2.
[0086] "Unknown impurities" refer to impurities, degradation products and chemical impurities classified as "B" and "A" in the European Pharmacopoeia and "A" and "E" in the United States Pharmacopoeia (USP).
[0087] The results obtained show that the compositions according to the invention are more stable than the compositions of the prior art. Thus, the composition according to the invention meets th...
Embodiment 3
[0088] Example 3: Antimicrobial properties of compositions according to the invention
[0089] Antimicrobial efficacy was assessed according to European monographs.
[0090] The following compositions (A to I according to the invention and counter-examples according to CE1 to CE7) were prepared according to the procedure of Example 1.
[0091]
[0092] Table 3: Efficacy of different batches of antimicrobial storage using 0.2% carbomer and different amounts of propylene glycol. NC = not applicable, C = applicable.
[0093]
[0094]Table 4: Efficacy of different batches of antimicrobial storage using 1% HEC and different amounts of propylene glycol. NC = not applicable, C = applicable.
[0095]
[0096]
[0097] Table 5: Efficacy of different batches for antimicrobial storage using 0.3% xanthan gum and different amounts of propylene glycol. NC = not applicable, C = applicable.
[0098]
[0099] Table 6: Evaluation of the antimicrobial efficacy of propylene gl...
PUM
Property | Measurement | Unit |
---|---|---|
viscosity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com